Organogenesis Holdings Inc
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
During the three months ended March 31, 2025, no director or officer of the Company other than Gary S. Gillheeney, Sr. and Antonio S. Montecalvo adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-rule 10b5-1 trading arrangement,” as each term is defined in item 408(a) of Regulation S-K.
On March 12, 2025, Mr. Gillheeney adopted a trading plan intended to satisfy Rule 10b5-1(c) to sell up to 827,688 shares of the Company’s Class A common stock issuable upon exercise of vested stock options between June 10, 2025 and March 31, 2026, subject to certain conditions.
On March 13, 2025, Mr. Montecalvo adopted a trading plan intended to satisfy Rule 10b5-1(c) to sell up to 40,708 shares of the Company’s Class A common stock and up to 159,292 shares of the Company’s Class A common stock issuable upon exercise of vested stock options between June 13, 2025 and March 13, 2026, subject to certain conditions.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.